Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.

Eng MS, Kaur J, Prasmickaite L, Engesæter BØ, Weyergang A, Skarpen E, Berg K, Rosenblum MG, Mælandsmo GM, Høgset A, Ferrone S, Selbo PK.

Photochem Photobiol Sci. 2018 Mar 22. doi: 10.1039/C7PP00358G. [Epub ahead of print]

PMID:
29565434
2.

Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide.

Øverbye A, Holsæter AM, Markus F, Škalko-Basnet N, Iversen TG, Torgersen ML, Sønstevold T, Engebraaten O, Flatmark K, Mælandsmo GM, Skotland T, Sandvig K.

Oncotarget. 2017 Aug 12;8(44):76921-76934. doi: 10.18632/oncotarget.20217. eCollection 2017 Sep 29.

3.

Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases.

Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K.

Oncotarget. 2017 Jul 18;8(44):76290-76304. doi: 10.18632/oncotarget.19350. eCollection 2017 Sep 29.

4.

Interrogating open issues in cancer medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Sep 15;17(10):632. doi: 10.1038/nrc.2017.85. [Epub ahead of print]

PMID:
28912576
5.

Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate.

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA, Hagene KT, Aas E, Lurås H, Johnsen-Soriano S, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Mælandsmo GM, Flatmark K.

ESMO Open. 2017 May 2;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017.

6.

Inhibition of PTP1B disrupts cell-cell adhesion and induces anoikis in breast epithelial cells.

Hilmarsdottir B, Briem E, Halldorsson S, Kricker J, Ingthorsson S, Gustafsdottir S, Mælandsmo GM, Magnusson MK, Gudjonsson T.

Cell Death Dis. 2017 May 11;8(5):e2769. doi: 10.1038/cddis.2017.177.

7.

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response.

Jernström S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perälä M, Mælandsmo GM, Sahlberg KK.

Breast Cancer (Dove Med Press). 2017 Mar 21;9:185-198. doi: 10.2147/BCTT.S115600. eCollection 2017.

8.

Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.

Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E, Sauer T, Mills GB, Kåresen R, Mælandsmo GM, Lingjærde OC, Frigessi A, Kristensen VN, Børresen-Dale AL, Sahlberg KK; OSBREAC.

Breast Cancer Res. 2017 Mar 29;19(1):44. doi: 10.1186/s13058-017-0812-y.

9.

Metabolic re-wiring of isogenic breast epithelial cell lines following epithelial to mesenchymal transition.

Halldorsson S, Rohatgi N, Magnusdottir M, Choudhary KS, Gudjonsson T, Knutsen E, Barkovskaya A, Hilmarsdottir B, Perander M, Mælandsmo GM, Gudmundsson S, Rolfsson Ó.

Cancer Lett. 2017 Jun 28;396:117-129. doi: 10.1016/j.canlet.2017.03.019. Epub 2017 Mar 18.

10.

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Apr;17(4):254-268. doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20. Review. Erratum in: Nat Rev Cancer. 2017 Sep 15;:.

PMID:
28104906
11.

Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer.

Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T; Oslo Breast Cancer Consortium (OSBREAC), Naume B, Borgen E, Mælandsmo GM.

Breast Cancer Res Treat. 2017 Feb;162(1):127-137. doi: 10.1007/s10549-016-4096-1. Epub 2017 Jan 5.

PMID:
28058579
12.

hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma.

Fleten KG, Flørenes VA, Prasmickaite L, Hill O, Sykora J, Mælandsmo GM, Engesæter B.

Cell Death Discov. 2016 Dec 12;2:16081. doi: 10.1038/cddiscovery.2016.81. eCollection 2016.

13.

Anti-angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between micro-computed tomography angiography and dynamic contrast enhanced MRI.

Kim E, Kim J, Maelandsmo GM, Johansen B, Moestue SA.

Magn Reson Med. 2017 Oct;78(4):1513-1522. doi: 10.1002/mrm.26547. Epub 2016 Nov 25.

PMID:
27888545
14.

Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases.

Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K.

Clin Exp Metastasis. 2017 Jan;34(1):51-62. doi: 10.1007/s10585-016-9829-3. Epub 2016 Nov 3.

PMID:
27812769
15.

Expression and clinical significance of Wee1 in colorectal cancer.

Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K.

Tumour Biol. 2016 Sep;37(9):12133-12140. Epub 2016 May 24.

PMID:
27220319
16.

Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma.

Westrøm S, Bønsdorff TB, Abbas N, Bruland ØS, Jonasdottir TJ, Mælandsmo GM, Larsen RH.

PLoS One. 2016 Oct 24;11(10):e0165382. doi: 10.1371/journal.pone.0165382. eCollection 2016.

17.

Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts.

Kristian A, Holtedahl JE, Torheim T, Futsaether C, Hernes E, Engebraaten O, Mælandsmo GM, Malinen E.

Mol Imaging Biol. 2017 Apr;19(2):271-279. doi: 10.1007/s11307-016-0998-x.

PMID:
27541026
18.

STAMP2 is required for human adipose-derived stem cell differentiation and adipocyte-facilitated prostate cancer growth in vivo.

Lindstad T, Qu S, Sikkeland J, Jin Y, Kristian A, Mælandsmo GM, Collas P, Saatcioglu F.

Oncotarget. 2016 Aug 9;8(54):91817-91827. doi: 10.18632/oncotarget.11131. eCollection 2017 Nov 3.

19.

Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer.

Rud AK, Boye K, Fodstad Ø, Juell S, Jørgensen LH, Solberg S, Helland Å, Brustugun OT, Mælandsmo GM.

Diagn Pathol. 2016 Jun 17;11(1):50. doi: 10.1186/s13000-016-0504-4.

20.

Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy.

Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K.

Cancer Med. 2016 Aug;5(8):1840-9. doi: 10.1002/cam4.766. Epub 2016 Jun 8.

21.

Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.

Kim E, Tunset HM, Cebulla J, Vettukattil R, Helgesen H, Feuerherm AJ, Engebråten O, Mælandsmo GM, Johansen B, Moestue SA.

BMC Cancer. 2016 Mar 7;16:191. doi: 10.1186/s12885-016-2225-1.

22.

Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors.

Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L.

Oncotarget. 2016 Apr 12;7(15):19997-20015. doi: 10.18632/oncotarget.7671.

23.

HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR.

Ingthorsson S, Andersen K, Hilmarsdottir B, Maelandsmo GM, Magnusson MK, Gudjonsson T.

Oncogene. 2016 Aug 11;35(32):4244-55. doi: 10.1038/onc.2015.489. Epub 2015 Dec 21.

24.

Zebrafish as a model system for characterization of nanoparticles against cancer.

Evensen L, Johansen PL, Koster G, Zhu K, Herfindal L, Speth M, Fenaroli F, Hildahl J, Bagherifam S, Tulotta C, Prasmickaite L, Mælandsmo GM, Snaar-Jagalska E, Griffiths G.

Nanoscale. 2016 Jan 14;8(2):862-77. doi: 10.1039/c5nr07289a.

PMID:
26648525
25.

Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.

Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA.

Oncotarget. 2016 Jan 12;7(2):1878-94. doi: 10.18632/oncotarget.6479.

26.

Construction of a plasmid coding for green fluorescent protein tagged cathepsin L and data on expression in colorectal carcinoma cells.

Tamhane T, Wolters BK, Illukkumbura R, Maelandsmo GM, Haugen MH, Brix K.

Data Brief. 2015 Sep 30;5:468-75. doi: 10.1016/j.dib.2015.09.022. eCollection 2015 Dec.

27.

From autonomy to community; new perspectives on tumorigenicity and therapy resistance.

Skrbo N, Tenstad E, Mælandsmo GM, Sørlie T, Andersen K.

Cancer Treat Rev. 2015 Dec;41(10):809-13. doi: 10.1016/j.ctrv.2015.10.004. Epub 2015 Oct 20. Review.

PMID:
26519005
28.

Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes.

Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM.

Clin Exp Metastasis. 2015 Dec;32(8):755-67. doi: 10.1007/s10585-015-9742-1. Epub 2015 Sep 9.

PMID:
26349943
29.

Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells.

Tamhane T, Lllukkumbura R, Lu S, Maelandsmo GM, Haugen MH, Brix K.

Biochimie. 2016 Mar;122:208-18. doi: 10.1016/j.biochi.2015.09.003. Epub 2015 Sep 3.

30.

Metabolic reprogramming supports the invasive phenotype in malignant melanoma.

Bettum IJ, Gorad SS, Barkovskaya A, Pettersen S, Moestue SA, Vasiliauskaite K, Tenstad E, Øyjord T, Risa Ø, Nygaard V, Mælandsmo GM, Prasmickaite L.

Cancer Lett. 2015 Sep 28;366(1):71-83. doi: 10.1016/j.canlet.2015.06.006. Epub 2015 Jun 18.

PMID:
26095603
31.

Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial.

Prasmickaite L, Berge G, Bettum IJ, Aamdal S, Hansson J, Bastholt L, Øijordsbakken M, Boye K, Mælandsmo GM.

Cancer Immunol Immunother. 2015 Jun;64(6):769-76. doi: 10.1007/s00262-015-1686-4. Epub 2015 Apr 2.

PMID:
25832001
32.

STAMP2 increases oxidative stress and is critical for prostate cancer.

Jin Y, Wang L, Qu S, Sheng X, Kristian A, Mælandsmo GM, Pällmann N, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Fazli L, Rennie P, Risberg B, Wæhre H, Danielsen HE, Ozpolat B, Saatcioglu F.

EMBO Mol Med. 2015 Mar;7(3):315-31. doi: 10.15252/emmm.201404181.

33.

High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting.

Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K.

Eur J Cancer. 2015 Jan;51(1):9-17. doi: 10.1016/j.ejca.2014.10.020. Epub 2014 Nov 11.

PMID:
25466510
34.

Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft.

Skrbo N, Hjortland GO, Kristian A, Holm R, Nord S, Prasmickaite L, Engebraaten O, Mælandsmo GM, Sørlie T, Andersen K.

PLoS One. 2014 Nov 24;9(11):e113278. doi: 10.1371/journal.pone.0113278. eCollection 2014.

35.

Poly(sebacic anhydride) nanocapsules as carriers: effects of preparation parameters on properties and release of doxorubicin.

Bagherifam S, Griffiths GW, Mælandsmo GM, Nyström B, Hasirci V, Hasirci N.

J Microencapsul. 2015;32(2):166-74. doi: 10.3109/02652048.2014.973073. Epub 2014 Oct 17.

PMID:
25323326
36.

pH-responsive nano carriers for doxorubicin delivery.

Bagherifam S, Skjeldal FM, Griffiths G, Mælandsmo GM, Engebråten O, Nyström B, Hasirci V, Hasirci N.

Pharm Res. 2015 Apr;32(4):1249-63. doi: 10.1007/s11095-014-1530-0. Epub 2014 Oct 7.

PMID:
25288014
37.

Patient-derived xenograft models: an emerging platform for translational cancer research.

Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A.

Cancer Discov. 2014 Sep;4(9):998-1013. doi: 10.1158/2159-8290.CD-14-0001. Epub 2014 Jul 15. Review.

38.

Synthesis, characterization, and cellular uptake of magnetic nanocarriers for cancer drug delivery.

Momtazi L, Bagherifam S, Singh G, Hofgaard A, Hakkarainen M, Glomm WR, Roos N, Mælandsmo GM, Griffiths G, Nyström B.

J Colloid Interface Sci. 2014 Nov 1;433:76-85. doi: 10.1016/j.jcis.2014.07.013. Epub 2014 Jul 24.

PMID:
25112915
39.

Positron emission tomography and pharmacokinetics of 2-[18F]-fluoroethyl choline for metabolic studies in breast cancer xenografts.

Kristian A, Riss P, Qu H, Milde M, Schoultz BW, Engebraaten O, Mælandsmo GM, Malinen E.

Acta Oncol. 2014 Aug;53(8):1086-92. doi: 10.3109/0284186X.2014.934398. Epub 2014 Jul 14.

PMID:
25017377
40.

Dynamic (18) F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts.

Kristian A, Nilsen LB, Røe K, Revheim ME, Engebråten O, Mælandsmo GM, Holm R, Malinen E, Seierstad T.

Nucl Med Mol Imaging. 2013 Sep;47(3):173-80. doi: 10.1007/s13139-013-0211-y. Epub 2013 Jun 21.

41.

In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts.

Esmaeili M, Moestue SA, Hamans BC, Veltien A, Kristian A, Engebråten O, Maelandsmo GM, Gribbestad IS, Bathen TF, Heerschap A.

J Magn Reson Imaging. 2015 Mar;41(3):601-9. doi: 10.1002/jmri.24588. Epub 2014 Feb 14.

PMID:
24532410
42.

Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.

Grinde MT, Skrbo N, Moestue SA, Rødland EA, Borgan E, Kristian A, Sitter B, Bathen TF, Børresen-Dale AL, Mælandsmo GM, Engebraaten O, Sørlie T, Marangoni E, Gribbestad IS.

Breast Cancer Res. 2014 Jan 21;16(1):R5. doi: 10.1186/bcr3597.

43.

Metastasis-associated protein S100A4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties.

Bettum IJ, Vasiliauskaite K, Nygaard V, Clancy T, Pettersen SJ, Tenstad E, Mælandsmo GM, Prasmickaite L.

Cancer Lett. 2014 Mar 1;344(1):28-39. doi: 10.1016/j.canlet.2013.10.036. Epub 2013 Nov 8.

PMID:
24215866
44.

Osteopontin is a prognostic biomarker in non-small cell lung cancer.

Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM.

BMC Cancer. 2013 Nov 11;13:540. doi: 10.1186/1471-2407-13-540.

45.

Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations.

Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM, Engebraaten O.

Clin Cancer Res. 2014 Jan 15;20(2):404-12. doi: 10.1158/1078-0432.CCR-13-1865. Epub 2013 Nov 5.

46.

Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts.

Bruheim S, Sandvold ML, Mælandsmo GM, Fodstad O.

Anticancer Res. 2013 Sep;33(9):3615-21.

PMID:
24023287
47.

Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts.

Kristian A, Revheim ME, Qu H, Mælandsmo GM, Engebråten O, Seierstad T, Malinen E.

Acta Oncol. 2013 Oct;52(7):1566-72. doi: 10.3109/0284186X.2013.813634. Epub 2013 Aug 29.

PMID:
23984812
48.

Clinical significance of disseminated tumour cells in non-small cell lung cancer.

Rud AK, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K.

Br J Cancer. 2013 Sep 3;109(5):1264-70. doi: 10.1038/bjc.2013.450. Epub 2013 Aug 13.

49.

Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.

Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Mælandsmo GM, Akslen LA, Gribbestad IS.

J Magn Reson Imaging. 2013 Nov;38(5):1043-53. doi: 10.1002/jmri.24079. Epub 2013 Mar 21.

PMID:
23908122
50.

Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts.

Esmaeili M, Bathen TF, Engebråten O, Mælandsmo GM, Gribbestad IS, Moestue SA.

Magn Reson Med. 2014 Jun;71(6):1973-81. doi: 10.1002/mrm.24869. Epub 2013 Jul 22.

PMID:
23878023

Supplemental Content

Loading ...
Support Center